Callan Capital’s ImmunityBio IBRX Stock Holding History

Callan Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$36.3K	Hold	12,055	–	–	﹤0.01%	363
2024 Q4	$30.9K	Hold	12,055	–	–	﹤0.01%	341
2024 Q3	$44.8K	Hold	12,055	–	–	﹤0.01%	347
2024 Q2	$76.2K	Buy	12,055 +1,500	+14%	+$9.89K	0.01%	308
2024 Q1	$56.7K	Hold	10,555	–	–	0.01%	295
2023 Q4	$53K	Hold	10,555	–	–	0.01%	231
2023 Q3	$17.8K	Buy	+10,555	New	+$21.2K	﹤0.01%	203
2016 Q4	–	Sell	-3,406,405	Closed	-$26.5M	–	42
2016 Q3	$26.5M	Sell	3,406,405 -356,681	-9%	-$2.66M	10.91%	3
2016 Q2	$23.4M	Hold	3,763,086	–	–	9.56%	3
2016 Q1	$30.9M	Buy	3,763,086 +38,573	+1%	+$364K	12.97%	3
2015 Q4	$64.5M	Buy	3,724,513 +92,052	+3%	+$1.37M	25.53%	1
2015 Q3	$41.6M	Buy	+3,632,461	New	+$79.3M	22.59%	1

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Callan Capital's IBRX Position: Q1 2025 in Review

Callan Capital held its ImmunityBio (IBRX) position steady in Q1 2025 at 12,055 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #363.

Callan Capital first reported a position in IBRX in Q3 2015 and has held it in 12 quarters since. The position peaked at $64.5M in Q4 2015. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

Callan Capital held 12,055 shares of ImmunityBio worth $36.3K as of Q1 2025.
Callan Capital left its ImmunityBio share count unchanged in Q1 2025.
ImmunityBio made up ﹤0.01% of Callan Capital's portfolio in Q1 2025, its #363 holding.
Callan Capital first reported a position in ImmunityBio in Q3 2015 and has held it in 12 quarters since.
Callan Capital's ImmunityBio position peaked at $64.5M in Q4 2015.
210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.